Bank of America Securities Sticks to Its Hold Rating for Y-Mabs Therapeutics (YMAB)

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $64.00. The company’s shares opened today at $12.96.

According to TipRanks, Stranahan is a 3-star analyst with an average return of 3.6% and a 54.76% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Xencor, and Krystal Biotech.

Currently, the analyst consensus on Y-Mabs Therapeutics is a Strong Buy with an average price target of $23.00.

Based on Y-Mabs Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $23.36 million and a GAAP net loss of $988 thousand. In comparison, last year the company earned a revenue of $31.45 million and had a net profit of $1.16 million

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Y-Mabs Therapeutics (YMAB) Company Description:

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.